Product Images Sacubitril And Valsartan

This is a description of a pharmaceutical product called Sacubitril and Valsartan Tablets. Each film-coated tablet contains 24 mg of sacubitril and 26 mg of valsartan. The usual dosage should be followed as per prescribing information available. It should be stored at a temperature of 20°C to 25°C. It should be kept away from moisture and out of the reach of children. The medication guide is available on the website provided. For any queries, you can contact the US number provided.*

The text provides detailed information about a pharmaceutical product containing sacubitril and valsartan in tablet form with film coating. Each tablet contains 24 mg of sacubitril and 26 mg of valsartan. It includes instructions for storage, dosage, and contact information for XLCare Pharmaceuticals Inc. Available medication guides from the manufacturer can be found online.*

This information is for XLcare Pharmaceuticals Inc.'s product - Sacubitril and Valsartan Tablets containing 49 mg of sacubitril and 51 mg of valsartan. The prescription-only medication comes in a pack of 180 film-coated tablets. It is advised to store the tablets at 20° to 25°C and protect them from moisture. The medication guide can be accessed online, and a US contact number is provided for assistance. The product is manufactured for XLcare Pharmaceuticals Inc. by Evaric Pharmaceuticals Inc. at their facility in Hauppauge, New York, USA.*

This text is a description of a pharmaceutical product called Sacubitril and Valsartan Tablets. Each tablet contains 49 mg of sacubitril and 51 mg of valsartan. The recommended storage temperature is between 20° to 25°C. It is a prescription medication and the prescribing information should be consulted for the usual dosage. The manufacturer is XLCare Pharmaceuticals Inc., located in Lawrenceville, GA, and the tablets are manufactured by Evaric Pharmaceuticals Inc. in Hauppauge, New York. More information can be found on their website and a Medication Guide is available. The contact number for the US is provided as 1-866-495-1995.*

This text is a description of a pharmaceutical product called "Sacubitril and Valsartan Tablets" by XLcare Pharmaceuticals Inc. Each film-coated tablet contains 97 mg of sacubitril and 103 mg of valsartan. The usual dosage instructions can be found in the prescribing information. It should be stored at 20° to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). It's important to protect the tablets from moisture and keep them out of reach of children. A medication guide is available at the provided website. For further inquiries, there is a U.S. contact number provided. The tablets are manufactured in the United States by Evaric Pharmaceuticals Inc.*

This text provides information about sacubitril and valsartan tablets manufactured by XLcare Pharmaceuticals Inc. Each tablet contains 97 mg of sacubitril and 103 mg of valsartan. It is a prescription medication with a recommended dosage as per the prescribing information. The tablets should be stored at 20° to 25°C and protected from moisture. The medication guide can be found on the website provided, and there is a contact number for inquiries. The manufacturer address is also included, showing they are based in Lawrenceville, GA, and the tablets are manufactured by Evaric Pharmaceuticals Inc. in Hauppauge, New York.*

This is a comparison of geometric mean ratios and 90% confidence intervals for a list of coadministered drugs. The text provides information on the relative change of each drug compared to a reference drug, such as Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil.*

This text presents data on the time to the first occurrence of cardiovascular death or heart failure hospitalizations in the PARADIGM-HF study. The results show a statistically significant difference (p<0.0001) between the treatment groups - Enalapril and Sacubitril/valsartan. The hazard ratio (HR) for Sacubitril and valsartan compared to Enalapril is 0.80 (95% CI: 0.73, 0.87), indicating a lower risk of events with Sacubitril/valsartan. The failure rate over time is depicted graphically, illustrating the outcomes in terms of risk at different time points since randomization.*

This data shows the time to occurrence of cardiovascular death in the PARADIGM-HF study. The Hazard Ratio (HR) with a 95% confidence interval was found to be 0.80 (0.71, 0.89). The failure rate (%) for Sacubitril and Valsartan and Enalapril is also provided over different time intervals. The number at risk and time since randomization in days for both treatments are shown in the table.*

This is a table presenting data on the time to the first occurrence of heart failure hospitalizations in the PARADIGM-HF study. It includes information such as the number at risk for both Sacubitril & Valsartan and Enalapril, as well as the hazard ratio and confidence interval. The table also shows the failure rate in percentage and the time since randomization in days at different intervals.*

This is not readable.*